This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Ginseng in Treatment of Fatigue in Multiple Sclerosis

This study has been completed.
Information provided by (Responsible Party):
Hamidreza Shemshaki, Isfahan University of Medical Sciences Identifier:
First received: October 19, 2012
Last updated: October 22, 2012
Last verified: October 2012
The purpose of this study was to evaluate the efficacy and safety of Ginseng in treatment of fatigue and Quality of Life of MS patients.

Condition Intervention Phase
Fatigue Drug: Ginseng Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Study of Ginseng in Treatment of Fatigue in Multiple Sclerosis

Resource links provided by NLM:

Further study details as provided by Hamidreza Shemshaki, Isfahan University of Medical Sciences:

Primary Outcome Measures:
  • Fatigue [ Time Frame: at 3 months after treatment ]
    Modified Fatigue Impact Scale (MFIS)is a21-item (score range of each item: 0-4) questionnaire with the total score computed from 0 (no impact of fatigue) to 84 (maximum impact of fatigue) in three subscales containing: physical (9 items), cognitive (10 items) and psychosocial (2 items) aspects.

Secondary Outcome Measures:
  • Quality Of Life [ Time Frame: at 3 months after treatment ]
    Quality Of Life Questionnaire (MSQOL-54) consisted of 54 questions (items), each one, assigned to a score ranging from 0 to 100.

Enrollment: 60
Study Start Date: December 2010
Study Completion Date: April 2011
Primary Completion Date: April 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Ginseng
Ginseng, tablet, 250 mg, twice, 3 months
Drug: Ginseng
it is kind of drug
Placebo Comparator: Placebo
Placebo, tablet
Drug: Placebo
it is placebo

Detailed Description:
Multiple Sclerosis (MS) is one of the most common non-traumatic causes of disability in the world. It is a chronic inflammatory and demyelinating disorder of the Central Nervous System (CNS) which affects individuals in the productive ages and causes a large burden for years to come. Fatigue is a common complaint and one of the least understood symptoms of MS

Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • definite diagnosis of relapsing-remitting MS (RRMS) by the MacDonald criteria with a baseline of Expanded Disability Status Score (EDSS)of less than 5.0

Exclusion Criteria:

  • prior use of ginseng or any other tonic agents, glucocorticoids, warfarin, digoxin, aspirin, furosemide, caffeine, ephedra and anti-platelet agents within one month prior to enrollment;
  • Pregnancy or lactation;
  • history of renal failure; and,
  • lack of appropriate adherence to the study protocol.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01712373

Iran, Islamic Republic of
Al-zahra university hospital
Isfahan, Iran, Islamic Republic of, 7007
Sponsors and Collaborators
Isfahan University of Medical Sciences
Principal Investigator: mahboobe esfahani, MD MD, Research Assistant
  More Information

Additional Information:
Responsible Party: Hamidreza Shemshaki, research assistant, Isfahan University of Medical Sciences Identifier: NCT01712373     History of Changes
Other Study ID Numbers: ASD-1270
Study First Received: October 19, 2012
Last Updated: October 22, 2012

Keywords provided by Hamidreza Shemshaki, Isfahan University of Medical Sciences:
Multiple sclerosis
Quality of life

Additional relevant MeSH terms:
Multiple Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Signs and Symptoms processed this record on September 21, 2017